Literature DB >> 27766560

Dynamics of FLAIR Volume Changes in Glioblastoma and Prediction of Survival.

Rachel Grossman1, Nir Shimony2, Dror Shir2, Tal Gonen3, Razi Sitt2, Tali Jonas Kimchi4, Carmit Ben Harosh2, Zvi Ram2.   

Abstract

BACKGROUND: The extent of tumor resection (EOTR) calculated by enhanced T1 changes in glioblastomas has been previously reported to predict survival. However, fluid-attenuated inversion recovery (FLAIR) volume may better represent tumor burden. In this study, we report the first assessment of the dynamics of FLAIR volume changes over time as a predictive variable for post-resection overall survival (OS).
METHODS: Contemporary data from 103 consecutive patients with complete imaging and clinical data who underwent resection of newly diagnosed glioblastoma followed by the Stupp protocol between 2010 and 2013 were analyzed. Clinical, radiographic, and outcome parameters were retrieved for each patient, including magnetic resonance imaging (MRI)-based volumetric tumor analysis before, immediately after, and 3 months post-surgery.
RESULTS: OS rate was 17.6 months. A significant incremental OS advantage was noted, with as little as 85 % T1-weighted gadolinium-enhanced (T1Gd)-EOTR measured on contrast-enhanced MRI. Pre- and immediate postoperative FLAIR-based EOTR was not predictive of OS; however, abnormal FLAIR volume measured 3 months post-surgery correlated significantly with outcome when FLAIR residual tumor volume (RTV) was <19.3 cm3 and <46 % of baseline volume (p < 0.0001 for both). Age and isocitrate dehydrogenase (IDH)-1 mutation were predictive of OS (p < 0.0001, Cox proportional hazards).
CONCLUSIONS: OS correlated with the immediate postoperative T1Gd-EOTR measured by enhanced T1 MRI, but not by FLAIR volume. Diminished abnormal FLAIR volume at 3 months post-surgery was associated with OS benefit when FLAIR-RTV was <19.3 cm3 or <46 % of baseline. These threshold values provide a new radiological variable that can be used for prediction of OS in patients with glioblastoma immediately after completion of standard chemoradiation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27766560     DOI: 10.1245/s10434-016-5635-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

1.  A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma.

Authors:  Christina Jackson; John Choi; Adham M Khalafallah; Carrie Price; Chetan Bettegowda; Michael Lim; Gary Gallia; Jon Weingart; Henry Brem; Debraj Mukherjee
Journal:  J Neurooncol       Date:  2020-06-19       Impact factor: 4.130

Review 2.  Supratotal Resection of Gliomas With Awake Brain Mapping: Maximal Tumor Resection Preserving Motor, Language, and Neurocognitive Functions.

Authors:  Kazuya Motomura; Fumiharu Ohka; Kosuke Aoki; Ryuta Saito
Journal:  Front Neurol       Date:  2022-05-12       Impact factor: 4.086

3.  Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.

Authors:  Patrick Grossmann; Vivek Narayan; Ken Chang; Rifaquat Rahman; Lauren Abrey; David A Reardon; Lawrence H Schwartz; Patrick Y Wen; Brian M Alexander; Raymond Huang; Hugo J W L Aerts
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

4.  Quantification of glioblastoma mass effect by lateral ventricle displacement.

Authors:  Tyler C Steed; Jeffrey M Treiber; Michael G Brandel; Kunal S Patel; Anders M Dale; Bob S Carter; Clark C Chen
Journal:  Sci Rep       Date:  2018-02-12       Impact factor: 4.379

5.  In Vivo Biodistribution of Engineered Lipid Microbubbles in Rodents.

Authors:  Letizia Oddo; Gaio Paradossi; Barbara Cerroni; Carmit Ben-Harush; Eti Ariel; Francesco Di Meco; Zvi Ram; Rachel Grossman
Journal:  ACS Omega       Date:  2019-08-08

6.  Maximal surgical resection and adjuvant surgical technique to prolong the survival of adult patients with thalamic glioblastoma.

Authors:  Jaejoon Lim; YoungJoon Park; Ju Won Ahn; So Jung Hwang; Hyouksang Kwon; Kyoung Su Sung; Kyunggi Cho
Journal:  PLoS One       Date:  2021-02-04       Impact factor: 3.240

7.  Survival Benefit of Supratotal Resection in a Long-term Survivor of IDH-wildtype Glioblastoma: A Case Report and Literature Review.

Authors:  Junya Yamaguchi; Kazuya Motomura; Fumiharu Ohka; Kosuke Aoki; Kuniaki Tanahashi; Masaki Hirano; Lushun Chalise; Tomohide Nishikawa; Hiroyuki Shimizu; Atsushi Natsume; Toshihiko Wakabayashi; Ryuta Saito
Journal:  NMC Case Rep J       Date:  2021-11-02

8.  Multi-parametric and multi-regional histogram analysis of MRI: modality integration reveals imaging phenotypes of glioblastoma.

Authors:  Chao Li; Shuo Wang; Angela Serra; Turid Torheim; Jiun-Lin Yan; Natalie R Boonzaier; Yuan Huang; Tomasz Matys; Mary A McLean; Florian Markowetz; Stephen J Price
Journal:  Eur Radiol       Date:  2019-02-01       Impact factor: 5.315

9.  Monitoring Radiation Treatment Effects in Glioblastoma: FLAIR Volume as Significant Predictor of Survival.

Authors:  Matthew D Garrett; Ted K Yanagihara; Randy Yeh; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Sameer A Sheth; Adam M Sonabend; Tony J C Wang
Journal:  Tomography       Date:  2017-09

10.  In Vivo Toxicity Study of Engineered Lipid Microbubbles in Rodents.

Authors:  Gaio Paradossi; Letizia Oddo; Barbara Cerroni; Carmit Ben-Harush; Eti Ariel; Francesco Di Meco; Zvi Ram; Rachel Grossman
Journal:  ACS Omega       Date:  2019-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.